Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maxim's Maxamine Phase III data

MAXM's first U.S. Phase III study of its Maxamine histamine immune stimulant in combination with IL-2 compared to IL-2 alone hit one of two primary end points,

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE